

EARLY WARNING REPORT
Pursuant to Part 3 of National Instrument 62-103

1. Security and Reporting Issuer

- 1.1 **State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.**

Common shares of Ocumetics Technology Corp. (formerly Quantum Blockchain Technologies Ltd.) (the “**Corporation**”), 2041 Everett Street, Abbotsford, BC V2S 7S1.

- 1.2 **State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.**

The common shares of the Corporation (“**Common Shares**”) are listed on the TSX Venture Exchange.

2. Name and Address of Acquiror:

- 2.1 **State the name and address of the acquiror**

Garth Webb
23544 - 20th Avenue
Langley, British Columbia
V2Z 2Z7

- 2.2 **State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.**

On August 27, 2021, Ventura Holdings Ltd., a corporation wholly owned by Garth Webb, received an aggregate of 43,200,000 common shares in the share capital of the Corporation (“**Common Shares**”) as a result of the amalgamation of the Corporation with Ocumetics Technology Corp. and the wholly-owned subsidiary of the Corporation (the “**Amalgamation**”), which shares comprise 39.90% of the issued and outstanding shares of the Corporation, or 36.11%, fully diluted.

Dr. Webb also acquired incentive stock options on August 27, 2021, which options entitle him to purchase up to 1,623,950 Common Shares at a price of \$0.125 per share for a period of five years (the “**Webb Options**”). The Common Shares underlying the Webb Options comprise 1.50% of the issued and outstanding Common Shares of the Corporation or 1.36%, fully diluted.

- 2.3 **State the names of any joint actors.**

Ventura Holdings Ltd.

3. Interest in Securities of the Reporting Issuer

- 3.1 **State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file the report and the change in the acquiror’s securityholding percentage in the class of securities.**

Dr. Webb acquired 43,200,000 Common Shares pursuant to the Amalgamation and options to purchase up to 1,623,950 Common Shares.

Prior to the Amalgamation and grant of options, Dr. Webb owned no securities of the Corporation of any kind.

As a result of the Amalgamation and grant of options, Dr. Webb now owns 43,200,000 Common Shares, comprising 39.90% of the issued and outstanding shares of the Corporation, or 36.11%, fully diluted and options which entitle him to purchase an additional 1,623,950 Common Shares.

- 3.2 State whether the acquiror acquired or disposed ownership of, or acquired or ceased to have control over, the securities that triggered the requirement to file the report.**

Dr. Webb acquired 43,200,000 Common Shares pursuant to the Acquisition and was granted options to purchase up to 1,623,950 Common Shares.

- 3.3 If the transaction involved a securities lending arrangement, state that fact.**

N/A

- 3.4 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.**

See item 3.1, above.

- 3.5 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities referred to in Item 3.4 over which**

- (a) the acquiror, either alone or together with any joint actors, has ownership and control**

See item 3.1 above.

- (b) the acquiror, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the acquiror or any joint actor, and**

N/A

- (c) the acquiror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

N/A

- 3.6 If the acquiror or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the acquiror's securityholdings.**

N/A

- 3.7 **If the acquiror or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement. State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.**

N/A

- 3.8 **If the acquiror or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the acquiror's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.**

N/A

4. Consideration Paid

- 4.1 **State the value, in Canadian dollars, of any consideration paid or received per security and in total.**

The Common Shares acquired by Dr. Webb under the Amalgamation were issued at a deemed price of \$0.125 per share. The options were issued as incentive stock options for no consideration.

- 4.2 **In the case of a transaction or other occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, disclose the nature and value, in Canadian dollars, of the consideration paid or received by the acquiror.**

See item 4.1 above.

- 4.3 **If the securities were acquired or disposed of other than by purchase or sale, describe the method of acquisition or disposition.**

See item 2.2, above, with respect to the Common Shares acquired under the Amalgamation.

5. Purpose of the Transaction

State the purpose or purposes of the acquiror and any joint actors for the acquisition or disposition of securities of the reporting issuer.

See item 2.2, above.

Describe any plans or future intentions which the acquiror and any joint actors may have which relate to or would result in any of the following:

- (a) **the acquisition of additional securities of the reporting issuer, or the disposition of securities of the reporting issuer;**

In the future, Dr. Webb may acquire additional securities of the Corporation, dispose of some or all of the securities he now owns or controls, or may continue to hold his current position.

- (b) a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries;**

N/A

- (c) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;**

N/A

- (d) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;**

N/A

- (e) a material change in the present capitalization or dividend policy of the reporting issuer;**

N/A

- (f) a material change in the reporting issuer's business or corporate structure;**

N/A

- (g) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company;**

N/A

- (h) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;**

N/A

- (i) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;**

N/A

- (j) a solicitation of proxies from securityholders;**

N/A

- (k) an action similar to any of those enumerated above.**

N/A

6. **Agreements, Arrangements, Commitments or Understanding With Respect to Securities of the Reporting Issuer.** Describe the material terms of any agreements, arrangements, commitments or understandings between the acquiror and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities, except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

N/A

7. **Change in material fact.** If applicable, describe any change in a material fact set out in a previous report filed by the acquiror under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

N/A.

8. **Exemption.** If the acquiror relies on an exemption from requirements in securities legislation applicable to formal bids for the transaction, state the exemption being relied on and describe the facts supporting that reliance.

N/A.

9. **Certification.** I, as the acquiror, certify, or I, as the agent filing the report on behalf of an acquiror, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

DATED: August 31, 2021

(Signed) "*Garth Webb*"

GARTH WEBB